Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Harbour BioMed a global biopharmaceutical company committed to the discovery development and commercialization of novel antibody therapeutics focusing
Vir Biotechnology Inc today announced that the US Food and Drug Administration has cleared its investigational new drug application and granted Fast Track designation for the combination
Synaptogenix Inc an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders today announced that the Food Drug Administration
Tempus AI Inc a leader in artificial intelligence and precision medicine today announced a new collaboration with United Therapeutics a leading biotechnology
Halozyme Therapeutics Inc today announced that Roche received European Commission marketing authorization of OCREVUS SC coformulated
Novo Nordisk today announced plans to invest billion US dollars to build a second fill and finishing manufacturing facility in Clayton North Carolina and grow its ability to produce current and future injectable treatments
Rigel Pharmaceuticals Inc today announced the completion of the transfer to Rigel of the New Drug Application for GAVRETO for the treatment of adult patients with metastatic rearranged during transfection
Novavax Inc a global company advancing proteinbased vaccines with its MatrixM adjuvant today announced that it has filed for a type II variation of existing
NurExone Biologic Inc a pioneering biopharmaceutical company welcomes Dr Yona Geffen as a consultant to support the Companys preclinical and clinical activities Dr Geffen who currently
HUTCHMED Limited today announces that its partner Takeda has received notification from the European Commission that it has approved FRUZAQLA as a monotherapy indicated for the treatment of adult patients with metastatic
